Eyevensys

company

About

Eyevensys creates ophthalmic therapeutic bio factories to sustainably treat major eye diseases.

  • 1 - 10

Details

Last Funding Type
Series B
Last Funding Money Raised
$30M
Industries
Biotechnology,Medical Device,Therapeutics
Founded date
Jan 1, 2008
Number Of Employee
1 - 10
Operating Status
Active

Eyevensys is a address critical unmet needs in ophthalmology by providing a much better way of delivering ophthalmic drugs that overcomes the limitations of current options, such as intravitreal injections, surgery, intravitreal implants and biodegradable formulations. All of these current options have their drawbacks, given they are invasive procedures. Eyevensys’ goal is not only to improve short and long term therapeutic outcomes, but also to enhance compliance, improve ocular bioavailability and tolerability.

They plan to build a high value product pipeline by enabling sustained production of therapeutic proteins in the eye that will deliver improved clinical outcomes while reducing the burden of frequent intravitreal or systemic injections and other invasive procedures.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$30M
Eyevensys has raised a total of $30M in funding over 2 rounds. Their latest funding was raised on Jan 8, 2020 from a Series B round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Jan 8, 2020 Series B $30M 2 Detail
Jun 30, 2015 Seed 1 Detail

Investors

Number of Lead Investors
Number of Investors
2
Eyevensys is funded by 2 investors. Global health sciences venture fund and Inserm Transfert Initiative are the most recent investors.
Investor Name Lead Investor Funding Round
Global health sciences venture fund Series B
Inserm Transfert Initiative Series B